<?xml version="1.0" encoding="UTF-8"?>
<p id="p0178" num="0178" sourceFile="EP 2055703A1.xml">
  <tables id="tabl0017" num="0017">
    <table frame="all">
      <title>[Table 4]</title>
      <tgroup cols="3">
        <colspec colnum="1" colname="col1" colwidth="23mm"/>
        <colspec colnum="2" colname="col2" colwidth="32mm"/>
        <colspec colnum="3" colname="col3" colwidth="71mm"/>
        <thead>
          <row>
            <entry align="center" valign="middle">Compound</entry>
            <entry align="center" valign="middle">Single dose (mg/kg)</entry>
            <entry align="center" valign="middle">Average CETP activity ± standard deviation (%)</entry>
          </row>
        </thead>
        <tbody>
          <row>
            <entry valign="middle">Control</entry>
            <entry align="center" valign="middle">-</entry>
            <entry align="center" valign="middle">43.5 ± 6.4</entry>
          </row>
          <row>
            <entry valign="middle">Example 10</entry>
            <entry align="center" valign="middle">100</entry>
            <entry align="center" valign="middle">11.4 ± 6.0</entry>
          </row>
          <row>
            <entry valign="middle">Example 13</entry>
            <entry align="center" valign="middle">100</entry>
            <entry align="center" valign="middle">9.0 ± 1.7</entry>
          </row>
        </tbody>
      </tgroup>
    </table>
  </tables> From the aforementioned test results, it was revealed that the pyrimidine compounds of the present invention having a benzyl(pyridylmethyl)amine structure, salts thereof and solvates thereof had superior CETP inhibitory activity also in living bodies.
</p>
